Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4559795
Max Phase: Preclinical
Molecular Formula: C75H124BrN27O17
Molecular Weight: 1755.89
Molecule Type: Unknown
Associated Items:
ID: ALA4559795
Max Phase: Preclinical
Molecular Formula: C75H124BrN27O17
Molecular Weight: 1755.89
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NC(C)(C)C(=O)N[C@@H](Cc1ccc(Br)cc1)C(=O)O
Standard InChI: InChI=1S/C75H124BrN27O17/c1-6-7-16-48(66(114)101-75(4,5)71(120)100-53(70(118)119)35-42-22-24-43(76)25-23-42)95-67(115)55-20-13-32-102(55)58(106)38-90-60(108)46(17-8-9-28-77)93-64(112)52(36-44-37-86-40-91-44)98-65(113)54(39-104)99-63(111)51(34-41(2)3)97-61(109)47(18-11-30-88-73(82)83)94-68(116)56-21-14-33-103(56)69(117)50(19-12-31-89-74(84)85)96-62(110)49(26-27-57(79)105)92-59(107)45(78)15-10-29-87-72(80)81/h22-25,37,40-41,45-56,104H,6-21,26-36,38-39,77-78H2,1-5H3,(H2,79,105)(H,86,91)(H,90,108)(H,92,107)(H,93,112)(H,94,116)(H,95,115)(H,96,110)(H,97,109)(H,98,113)(H,99,111)(H,100,120)(H,101,114)(H,118,119)(H4,80,81,87)(H4,82,83,88)(H4,84,85,89)/t45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-/m0/s1
Standard InChI Key: PRXYKDJXBHAHRT-DMJQPPRDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1755.89 | Molecular Weight (Monoisotopic): 1753.8852 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Fischer C, Lamer T, Wang W, McKinnie SMK, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC.. (2019) Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents., 166 [PMID:30690406] [10.1016/j.ejmech.2019.01.040] |
Source(1):